Hostname: page-component-cd9895bd7-p9bg8 Total loading time: 0 Render date: 2024-12-24T20:01:59.040Z Has data issue: false hasContentIssue false
  • English
  • Français

The treatment of mixed states and the risk of switching to depression

Published online by Cambridge University Press:  16 April 2020

Eduard Vieta
Eduard Vieta*
Affiliation:
Department of Psychiatry, Hospital Clinic, IDIBAPS, Clinical Institute of Neuroscience, University of Barcelona, Villarroel 170/Rossello 140, 8036Barcelona, Spain
*
E-mail address: [email protected] (E. Vieta).
Get access

Abstract

There are few controlled studies evaluating the treatment of bipolar mixed states. Evidence suggests that mixed states may be more responsive to some anticonvulsants than to lithium. Olanzapine alone or in combination with divalproate or lithium has been adequately evaluated in randomized clinical trials involving mixed-state patients, whereas risperidone and quetiapine have not. There is also some evidence demonstrating the efficacy of ziprasidone and aripiprazole. The risk of switching to depression is high in mixed states. Conventional antipsychotics, such as haloperidol, may be less efficacious at protecting against a switch to depression than atypical antipsychotics, divalproate or lithium. When choosing drugs for the treatment of mania, and especially for the treatment of mixed states, their efficacy against manic and depressive symptoms, and their safety in terms of the risk of switching to depression should be taken into account.

Keywords

DepressionDivalproateLamotrigineMixed statesOlanzapinePsychoeducation
Type
Review
Information
European Psychiatry , Volume 20 , Issue 2 , March 2005 , pp. 96 - 100
Copyright
Copyright © Elsevier SAS 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bowden, CL, Calabrese, JR, Sachs, G, Yatham, LN, Asghar, SA, Hompland, Met al.A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch. Gen. Psychiatry 2003; 60:392–400.CrossRefGoogle ScholarPubMed
Calabrese, JR, Keck, PE, Macfadden, W, Minkwitz, M, Ketter, TA, Weisler, RHet al.A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am. J. Psychiatry 2005 [in press]CrossRefGoogle ScholarPubMed
Ciapparelli, A, Dell’Osso, L, Tundo, A, Pini, S, Chiavacci, MC, Di Sacco, Iet al.Electroconvulsive therapy in medication-nonresponsive patients with mixed mania and bipolar depression. J. Clin. Psychiatry 2001; 62:552–555.CrossRefGoogle ScholarPubMed
Colom, F, Vieta, E, Martinez-Aran, A, Reinares, M, Goikolea, JM, Benabarre, Aet al.A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch. Gen. Psychiatry 2003; 60:402–407.CrossRefGoogle ScholarPubMed
Gyulai, L, Bowden, CL, McElroy, SL, Calabrese, JR, Petty, F, Swann, ACet al.Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 2003; 28:1374–1382.CrossRefGoogle ScholarPubMed
Hirschfeld, RM, Keck, PE Jr., Kramer, M, Karcher, K, Canuso, C, Eerdekens, Met al.Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am. J. Psychiatry 2004; 161:1057–1065.CrossRefGoogle ScholarPubMed
Hirschfeld, RM, Williams, JB, Spitzer, RL, Calabrese, JR, Flynn, L, Keck, PE Jr.et al.Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am. J. Psychiatry 2000; 157:1873–1875.CrossRefGoogle ScholarPubMed
Keller, MB, Lavori, PW, Coryell, W, Andreasen, NC, Endicott, J, Clayton, PJet al.Differential outcome of pure manic, mixed/cycling, and pure depressive episodes in patients with bipolar illness. J. Am. Med. Assoc. 1986; 255:3138–3142.CrossRefGoogle ScholarPubMed
Khanna, S, Vieta, E, Lyons, B, Grossman, F, Eerdekens, M, Kramer, MRisperidone in the treatment of acute bipolar mania: a double-blind, placebo-controlled study of 290 patients. Br. J. Psychiatry 2005 [in press]CrossRefGoogle Scholar
Kupfer, DJ, Frank, E, Grochocinski, , Mallinger, AGStabilization in the treatment of mania, depression and mixed states. Acta Neuropsychiatr. 2000; 12:110–114.CrossRefGoogle ScholarPubMed
Swann, AC, Bowden, CL, Morris, D, Calabrese, JR, Petty, F, Small, Jet al.Depression during mania. Treatment response to lithium or divalproex. Arch. Gen. Psychiatry 1997; 54:37–42.CrossRefGoogle ScholarPubMed
Tohen, MF, Greil, W, Calabrese, JR, Sachs, GS, Yatham, LN, Müller-Oerlinghausen, et al. Olanzapine versus lithium in relapse/recurrence prevention in bipolar disorder: a randomized double-blind controlled 12–month clinical trial. Am J Psychiatry (in press).Google Scholar
Tohen, M, Baker, RW, Altshuler, LL, Zarate, CA, Suppes, T, Ketter, TAet al.Olanzapine versus divalproex in the treatment of acute mania. Am. J. Psychiatry 2002; 159:1011–1017.CrossRefGoogle ScholarPubMed
Tohen, M, Chengappa, KN, Suppes, T, Baker, RW, Zarate, CA, Bowden, CLet al.Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser vs. mood stabiliser alone. Br. J. Psychiatry 2004; 184:337–345.CrossRefGoogle Scholar
Tohen, M, Chengappa, KN, Suppes, T, Zarate, CA Jr., Calabrese, JR, Bowden, CLet al.Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch. Gen. Psychiatry 2002; 59:62–69.CrossRefGoogle ScholarPubMed
Tohen, M, Goldberg, JF, Gonzalez-Pinto Arrillaga, AM, Azorin, JM, Vieta, E, Hardy-Bayle, MCet al.A 12-week, double-blind comparison of olanzapine vs. haloperidol in the treatment of acute mania. Arch. Gen. Psychiatry 2003; 60:1218–1226.CrossRefGoogle ScholarPubMed
Tohen, M, Jacobs, TG, Grundy, SL, McElroy, SL, Banov, MC, Janicak, PGet al.Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch. Gen. Psychiatry 2000; 57:841–849.CrossRefGoogle Scholar
Tohen, M, Sanger, TM, McElroy, SL, Tollefson, GD, Chengappa, KN, Daniel, DGet al.Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am. J. Psychiatry 1999; 156:702–709.Google ScholarPubMed
Vieta, EBipolar mixed states and their treatment. Exp. Rev. Neurother. 2005; 5:63–68.CrossRefGoogle ScholarPubMed
Vieta, E, Colom, FPsychological interventions in bipolar disorder: from wishful thinking to an evidence-based approach. Acta Psychiatr. Scand. 110Suppl 4222004 1–10.CrossRefGoogle Scholar
Vieta, E, Goikolea, JM, Corbella, B, Benabarre, A, Reinares, M, Martinez, Get al.Group for the Study of Risperidone in Affective Disorders (GSRAD). Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. J. Clin. Psychiatry 2001; 62:818–825.CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.